Skip to main content
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. — Investor Relations & Filings

Ticker · STOK ISIN · US86150R1077 LEI · 549300RD25SS2DIJHJ67 US Manufacturing
Open in API
Filings indexed 558 across all filing types
Latest filing 2024-06-17 Regulatory Filings
Country US United States of America
Listing US STOK

About Stoke Therapeutics, Inc.

https://www.stoketherapeutics.com/

Stoke Therapeutics, Inc. is a biotechnology company focused on developing treatments for severe genetic diseases by addressing their underlying cause. The company utilizes its proprietary research platform, TANGO (Targeted Augmentation of Nuclear Gene Output), an RNA-based approach designed to restore protein levels. This technology works by upregulating protein expression from the healthy copy of a gene to compensate for a mutated or non-functioning copy, a mechanism particularly suited for haploinsufficient diseases. Stoke's lead investigational medicine, zorevunersen (STK-001), is in late-stage clinical development for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company is also advancing its platform to treat other genetic conditions, including autosomal dominant optic atrophy (ADOA).

Recent filings

Filing Released Lang Actions
Regulatory Filings 2024
Regulatory Filings Classification · 100% confidence The document is a letter from Stoke Therapeutics, Inc. to the SEC requesting acceleration of effectiveness for a Registration Statement on Form S-3. It is a correspondence related to a regulatory filing process, specifically about the timing of a registration statement becoming effective. The document does not contain financial data, report content, or detailed disclosures typical of financial reports or earnings releases. It is a formal regulatory communication, not a report or presentation. The document length is short (1584 characters), and it is clearly a regulatory filing correspondence. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-06-17 English
Regulatory Filings 2024
Regulatory Filings Classification · 60% confidence The provided document text appears to be encoded or encrypted and does not contain any readable content, keywords, regulatory headers, or references to specific report types, fiscal periods, or regulatory bodies. Without any discernible information or context, it is impossible to classify the document as any specific filing type. According to the rules, when a document does not neatly fit into any specific category and lacks identifiable content, the fallback classification is Regulatory Filings (RNS). The document length is 15,000 characters, which is substantial, but the content is not interpretable. Therefore, the best classification is RNS with moderate confidence due to lack of content clarity.
2024-06-17 English
S-3
Capital/Financing Update Classification · 100% confidence The document is a Form S-3 Registration Statement filed with the SEC, dated June 13, 2024. It is a registration statement under the Securities Act of 1933 for the potential offer and sale of shares by selling stockholders. The text includes detailed information about the registration process, selling stockholders, plan of distribution, and legal disclaimers. It is not a financial report, earnings release, or management discussion. It is a capital markets filing related to securities registration and offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains the full registration statement, not just an announcement of a report.
2024-06-13 English
Director's Dealing 2024
Director's Dealing
2024-06-07 English
Director's Dealing 2024
Director's Dealing
2024-06-07 English
Director's Dealing 2024
Director's Dealing
2024-06-07 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.